Continued treatment with GLP2 for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial
Secretary of Health and Human Services announced that several peptides may be removed from the FDAs Category 2 compounding restriction list
But the company has said that growth is slowing and the stock price has declined quite a bit (really a measure of the fact that investors arent confident the companys future will be as strong)
Retatrutide needs Phase 3 data, FDA approval, cardiovascular outcomes studies, and years of post-market surveillance before it can match semaglutide's evidence base
Las clulas L detectan la presencia de AGCC, lo que desencadena la secrecin de GLP-1
This increased intestinal fluid production, combined with altered transit time, creates an environment where diarrhea becomes more likely